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iABSTRACT
Modified release multiparticulate pellets have been produced by the
process of extrusion and spheronisation for colon-targeted delivery of
cystamine, a cysteamine derivative. Orally ingested cysteamine
formulations used in the treatment of cystinosis, are observed to cause
gastrointestinal mucosa irritation leading to nausea, vomiting and
ulceration in patients on such therapies.
Spheronised pellets were prepared varying the type and concentration of
the polymer used as an extrusion aid in the formulation. Classes of
polymeric materials tested include starches, natural gums and cellulose
derivatives. The properties of each wet mass formulation, extrudate and
spheronisation product obtained were subsequently evaluated and
compared to that obtained from a standard extrusion aid, microcrystalline
cellulose. Viable pellets produced were subjected to detailed analytical
procedures that include: pellet size analysis, qualitative sphericity
determination, friability testing, bulk density measurements, optical and
scanning electron microscopy.
Amongst the polymers tested, blends of 60/40% and 65/35% low/high
acyl gellan gum (Kelcogel®) incorporated into lactose-based wet masses
produced good pellets with relatively high sphericity (percentage
sphericity: 65-70%).
Cystamine was subsequently incorporated into gellan and microcrystalline
cellulose pellets and efforts made to tailor the release profile of the drug
ii
by coating pellets with Eudragit® FS30D, a pH-sensitive polymer. The
dosage forms described should selectively deliver the drug to the colon
through pH-dependent dissolution of the polymer coating at colonic pH
conditions (pH 7.4) thereby minimising the incidence of any
gastrointestinal side effects. Dissolution results showed that Eudragit®
FS30D coated cystamine pellets released < 3% of incorporated drug in
0.01M HCl over 1 hour at gastric pH of 1.2, while > 90% of the drug was
released in phosphate buffer at pH 7.4. Indicating the suitability of these
coated pellets as potential colon-targeted dosage forms for delivery of
cysteamine.
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11. INTRODUCTION
1.1 Cystinosis
This is a rare genetic metabolic disorder characterised by an unusual
accumulation of the amino acid cystine within the lysosomes of human
cells. This condition is due to a defect in the normal lysosomal
transport mechanism for cystine caused by genetic mutation.
Continued cystine crystallisation within the cells of organs like the
kidneys, pancreas, and eyes, would eventually result in organ damage
and end-organ failure in such patients [1].
The condition can be treated pharmacologically, by the administration
of the drug cysteamine (available commercially as the bitartrate salt,
Cystagon ®). Cysteamine works by interacting with excess intracellular
cystine to form a cysteamine-cysteine disulphide complex spatially
identical in structure to the amino acid lysine, which means this
complex is subsequently transported out of the cell by the transport
mechanism for lysine. Unfortunately, oral cysteamine therapy is
affected by poor patient compliance due to various side effects caused
by its ingestion, as well as the offensive taste and smell of the drug.
On oral administration, cysteamine irritates the gastrointestinal
mucosa causing nausea, vomiting and ulceration; its metabolites are
also excreted in sweat and breath resulting in body odour and halitosis.
Scientists have attempted to deliver the drug as suppositories in a bid
2to overcome gastrointestinal (GIT) mucosa irritation [2]. But, the
inconvenience and unpredictability of drug absorption through the
rectal route are issues that limit the use of suppositories [3]. Intrarectal
drug administration has been associated with clinically significant
interpatient variations in peak blood levels [4]. This is undoubtedly a
consequence of the irregular pharmacokinetics of drugs delivered
through the rectal route.
Rectal drug absorption can be delayed or as rapid and complete as
intravenous bolus doses depending on factors like pH of the absorption
site, presence of stool in the rectal vault and formulation composition
[4]. Also, post-absorptive drug distribution and metabolism is not well-
defined because rectal venous drainage is different within the
rectosigmoid region [5]. Drugs administered high in the rectum are
drained by the superior rectal veins which carry them to the liver where
they are metabolised [5]. While, drugs administered further down the
rectum are delivered systemically via the inferior and middle rectal
veins prior to hepatic distribution [5]. Patients could also expel an
unestimated amount of the drug, making it difficult to optimise the
dose of the drug required for each patient or disease state [4].
Much research has also gone into eliminating the halitosis and body
odour caused by the drug through the use of pro-drugs which are
pharmacologically inactive, but are subsequently converted to the
active compound in-vivo [6].
3The cysteamine molecule lacks a chromophore and is hence UV
transparent. Therefore for the purpose of this research, cystamine, a
disulphide of cysteamine was tagged with a phenyalanine conjugate to
enable quantitative analysis/detection of the release of the active
pharmaceutical ingredient (API) by ultraviolet/visible spectroscopy.
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Figure 1: cystamine –phenylalanine conjugate
1.2 Oral Modified Release Dosage Forms (OMRDFS)
Oral modified release dosage forms (OMRDFS) are defined by the USP
as dosage forms whose drug release profiles of time course and/or
location are designed to facilitate therapeutic or convenience goals not
offered ordinarily by conventional dosage forms [7]. OMRDFs are
formulated to consist of an in-built chemical or physical drug release
barrier, responsible for regulating the release of the active
pharmaceutical ingredient (API) from the dosage form.
Based on the nature of this barrier, they are grouped as
monolithic/matrix systems where active drug particles are dispersed in
4a soluble or insoluble matrix, or reservoir and osmotic pump delivery
systems made up of drug units coated with a release-controlling
membrane.
OMRDFs can also be formulated as single unit, whole, non-
disintegrating dosage forms e.g. tablets and some capsules or as
mutiparticulates / multiple unit systems. Oral modified release dosage
forms lead to greater patient compliance as well as a reduction in
dosing frequency. Modified release dosage forms also significantly
reduce the risks of local irritation and side effects associated with dose
dumping. Thereby offering an overall enhancement in safety profile
and peak therapeutic performance of administered medication.
1.3 Multiparticulate Systems and Drug Delivery
Multiparticulate OMRDFs are spherical, free-flowing granules with a
narrow size distribution and mean diameter ranging between 0.7 and
2mm e.g. pellets, beads, and microspheres.
The in-vivo behaviour of orally ingested multiparticulate dosage forms,
have been extensively investigated by researchers using reliable
techniques like gamma scintigraphy based imaging technology [8, 9]
and multiparticulates have been shown to perform better as oral
modified release dosage forms than single–unit dosage forms.
Abrahamsson and co-workers found that multiparticulate pellets had
shorter mean gastric emptying times and longer mean colonic
residence times than tablets [10]. They also observed that they were
5more slowly and widely dispersed in the gastrointestinal tract, having
longer total transit times than tablets.
Mutiparticulates offer superb pharmacological and technological
advantages over conventional single unit dosage systems.
Therapeutically, drug absorption is optimised when dense, small-sized
multiparticulates are used in drug delivery, because they are observed
to have free passage and easy distribution along the GIT, facilitating
uniform drug absorption from the gut. The consequences of
therapeutic failure of orally administered medication due to failure of
the dosage form to release the drug are also significantly less. This is
because the failure of a single pellet to release the API will not result in
drastically compromised plasma concentrations of the drug, when
compared to if that was a single unit dosage form. Patient compliance
is also improved due to reduced systemic and local side effects.
In processing, pelletisation offers enhanced opportunities for
technological creativity. This technique has been used as a way of
limiting drug migration for low dose actives [11] and improving the
flowability and density of low density, finely divided APIs and
excipients to limit dust formation [12]. Good flow properties, improved
strength and density exhibited by pellets promote reproducible die and
capsule filling and ensure adequate content uniformity.
Also, pellets with differing release profiles/rates can be incorporated in
the same dosage unit by coating them in sub-batches with different
6materials; the fill weights of pellets can be adjusted to produce
formulations of different doses from the same batch [13] and several
actives or incompatible drugs can be combined in a single dosage unit.
Finally, coating is facilitated by the spherical shape, narrow size
distribution and low friability of pellets.
1.4 Colonic Drug Targeting
The colon has become an important site for the delivery and systemic
absorption of drugs that exercise their pharmacological effects at other
sites in the body. The most critical objective of a colon-targeted
formulation is ensuring that the drug is protected from release in the
upper portions of the GIT, while effecting abrupt release of the API on
reaching the colon.
In 1985, Hardy et al demonstrated that multiparticulate dosage forms
enabled the API to get to the colon faster than conventional single unit
dosage forms because their small sizes enable easy passage through
the pylorus reaching the colon faster [14]. Their smooth spherical
morphology also facilitates easy application of functional coatings, an
integral aspect of colonic drug targeting.
Colon-targeted formulations are often designed to take advantage of
certain factors called ‘trigger factors’. These factors and their effect on
colonic delivery are explained below.
71.4.1 рH-dependent systems
The terminal ileum and colon have a much higher рH than other
regions of the GI tract, hence drug delivery systems can be coated
with functional рH-sensitive polymeric coatings that will selectively
disintegrate and effect drug release at higher рH values of 6.8-7.5
[15].
Commonly used pH-sensitive coatings for colonic drug delivery are the
enteric coatings e.g. polyvinyl acetate phthalate and methacrylic acid
copolymers (Eudragits). It has been reported however that achieving
successful colon-specific drug release with рH-sensitive coatings alone
is not feasible. Eudragit S coated rapidly disintegrating tablets have
been observed to fail to disintegrate and release the drug due to drops
in рH of 7.0 to 6.0 from the terminal ileum to ascending colon
[16].This problem can be tackled by employing optimum combinations
of Eudragit L100 and S100 to enable selective drug release at desired
рH ranges between 6.0-7.0 . New copolymers like Eudragit P4135/FS
that offer a reduced risk of premature drug release by dissolving at
similar рH values to S100 but at a slower rate[16], and sensitive
radiotelemetry capsules that can accurately measure and determine
the most favourable рH for colonic drug targeting are new approaches
currently being evaluated [17].
1.4.2 Time dependent systems
These are based on timed release of the drug. Since small intestinal
transit times are fairly constant (maintained between 3-4hrs), when
compared to gastric emptying times and colonic transit times which are
8variable. A colon-targeted formulation developed by Gupta et al
containing 5-aminosalicylic acid, employed both рH sensitive coatings
and timed release to achieve successful colon-specific drug release
[18].
1.4.3 Pressure-responsive systems
A pressure controlled colonic delivery system made up of a dispersion
of the active drug particles in a suppository base with an ethylcellulose
coating has been described in the literature [19,20]. On oral ingestion,
the suppository base melts resulting in a fluid filled ethylcellulose
capsule that stays intact in the small intestine, but will rupture and
release the drug on exposure to the more intense contractions and
higher viscosity luminal conditions found in colonic regions.
1.4.4 Bacteria-dependent systems
The human colon is colonised by a large multitude and variety of
bacteria that produce enzymes that can be employed in achieving
colon-specific drug delivery. The drug is coated with a polymer
material that is selectively degraded by bacterial enzymes in the colon
to cause drug release. COLAL® technology which consists of a glassy
amylase coating resistant to degradation by small intestinal enzymes
but susceptible to breakdown by colonic bacteria, mixed with ethyl
cellulose to inhibit swelling has been used successfully to deliver
prednisolone metasulphobenzoate to the colon of patients suffering
from ulcerative colitis [21].
91.5 Pelletisation by Extrusion and Spheronisation
This multi-step process of manufacturing drug-loaded multiparticulate
pellets of about 1mm in diameter was introduced in the late 1960s,
and is a useful technique for producing robust high-quality pellets with
unique properties, often favoured for controlled drug release purposes
[22].
Though the process can be labour-intensive, its inherent intensive
mixing capabilities enables the incorporation of high concentrations of
the active within the granules (up to 90%) without the production of a
bulky dosage form. Thus allowing optimum utilisation of excipients and
lowering production costs. The pellets obtained can then either be filled
into hard gelatine capsules or compacted into tablets for immediate or
more often controlled release applications [23].
1.6 Excipients
Excipients are materials that are added to drug substances to aid
processing or to achieve formulation objectives like controlled release and
drug targeting. It is important to choose excipients that are compatible
with the drug, as well as able to confer desired extrusion characteristics
like cohesiveness and plasticity to the wet mass.
Excipients required for pelletisation by extrusion and spheronisation
include:
1.6.1 Extrusion Aids
These are materials added to the wet mass formulation to improve its
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rheological properties, making it suitable for extrusion and spheronisation.
Many materials have been evaluated for use as extrusion aids, especially
polymers.
Liew et al proposed the following properties as being required of a
material to be employed as an extrusion aid: water insolubility, large
surface area to foster interaction with other components of the
formulation, large water absorption and retention capacity, good
binding/cohesive properties and ability to facilitate drug release [24].
Other desirable properties include compatibility with a wide variety of APIs
and granulating fluids, preferably water.
Finally, the ideal extrusion aid should facilitate easy processing of the wet
mass to give a high yield of robust pellets that can withstand compression
and compaction forces required for tablet manufacture. Commonly used
extrusion aids include cellulose ethers, natural gums, starches and other
pharmaceutical polymers.
Cellulose derivatives
Cellulose derivatives used in dosage form manufacture include
hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose,
hydroxypropylcelluose and sodiumcarboxymethylcellulose.
The most effective and widely used cellulose derivative for extrusion and
spheronisation purposes is microcrystalline cellulose (MCC). Which
consists of a random aggregation of filamentous crystals that create a
high internal porosity and large surface area of about 130-270 m2/g within
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its structure [25].
This unique structure as well as the availability of free hydroxyl groups
that are able to form hydrogen bonds with water molecules confer high
water retention and absorption capacity on MCC and enable it to control
the movement of water through the wet mass [26]. Thereby, modifying
the rheological properties of other excipients and preventing phase
differentiation during extrusion. Water that is retained within the
amorphous regions of MCC can act as a plasticiser, enhancing molecular
flexibility by breaking up intramolecular hydrogen bonds [26]. Therefore,
MCC also imparts plasticity and cohesiveness on the moistened mass
enhancing the entire process of pellet manufacture. It is available
commercially as Avicel® in a range of grades.
However, MCC is expensive [27] and suffers disadvantages like
adsorption of some drugs to the surface of its fibres [28], chemical
incompatibility with certain drugs [29], prolonged pellet disintegration
when used with poorly soluble drugs (which poses a problem in the
formulation of controlled drug release systems) [30] and variability in the
properties of pellets produced with microcyrstalline cellulose from different
sources. This has prompted the need to investigate the possibility of
replacing MCC with other materials in the formulation of pellets by
extrusion.
Basit et al (1999), observed that for a certain formulation of ranitidine,
the decomposition of the active could be reduced to acceptable levels if
12
the concentration of microcyrstalline cellulose used in the formulation was
lowered and glycerylmonostearate added instead [31]. While, Linder and
Kleinebudde (1994) reported higher dissolution rates and porosity for
pellets produced with powdered cellulose than microcrystalline cellulose
[32].
Natural gums
These are polysaccharides obtained from natural sources like plants,
animals or even bacteria. A variety of natural gums have been evaluated
for potential application as extrusion aids in the formulation of wet masses
for extrusion, the common ones being agar, carrageenan and sodium
alginate [33].
Gellan gum, an anionic extracellular polysaccharide discovered by Kaneko
and Kang [34] in 1978 has been tested as an extrusion aid in lactose
based wet masses. It is obtained as exo-secretions when a carefully
formulated fermentation medium is inoculated with Sphingomonas
paucimobilis formerly referred to as Pseudomonas elodea, extracted from
the elodea plant tissue [35]. Native gellan gum is composed of repeating
units of β-D-glucose, L-rhamnose, D-glucuronic acid and two acyl groups
(acetate and glycerate) bound to the glucose residues adjacent to
glucuronic acid. These acyl components of gellan gum have significant
influence on the rheology of gellan gels and can be removed by
deacetylation of the gum by alkaline treatments to yield lower acyl gellan
gum derivatives [36].
13
Fig 2: Repeating units of chemical structure of native gellan gum
Gels from native gellan gum are soft, elastic, cohesive thermoreversible
gels, while deacetylated gellan gum often yields harder, brittle and more
thermostable gels. Gels with intermediate characteristics can be derived
by manipulating the degree of deacetylation [36].
There are three types of deacetylated gellan gum viz:
Kelcogel® CGHA: food grade, high acyl gellan gum.
Kelcogel® CGLA: food grade, low acyl gellan gum.
GelzanTm: low acyl gellan gum deproteinised and clarified for use as
microbiological media.
Sustained release beads prepared by gelation of gellan gum with calcium
ions were used for the delivery of metribuzin (a weed killer) and
theophylline. The gum was observed to prolong the release of the API in
acidic media, but facilitate rapid drug release in phosphate buffer (рH 7.4)
[37]. These properties should enhance successful colon specific drug
delivery.
Though research involving the use of gellan gum in pharmaceutical
dosage form manufacture is still in its infancy, the polymer has promising
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physical properties that can make it a suitable replacement for existing
polymers used not only in extrusion and spheronisation, but in a wide
variety of industries and applications.
1.6.2 Filler/diluents
These are added to increase the bulk volume or size of the dosage form.
Commonly used fillers for extrusion purposes are dibasic calcium
phosphate (Emcompress®) and lactose.
1.6.3 Binders
These are added to improve cohesion, increase plasticity and reduce
extrudate friability e.g. methylcellulose and
sodiumcarboxymethylcellulose. Funck et al (1991) observed that the
inclusion of low proportions of common binders enabled the production of
high drug loaded microcrystalline-based pellets [38]. It is however crucial
to optimise the amount of binders included in the formulation because
when high proportions of binders like sodium carboxymethylcellulose are
present in wet masses for extrusion, the mass acquires elastic rather than
plastic properties, leading to the formation of long coils of extrudate on
extrusion that do not deform into proper spheres when spheronised [25].
1.7 Formulation Development and Variables
The quality of the pellets produced at the end of the process is highly
formulation dependent and will ultimately be influenced by the
physicochemical properties and concentrations of the drug and excipients
employed and to a large extent, type and concentration of the granulating
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fluid used. Generally, the desired goal is to obtain a wet mass which is
cohesive and plastic enough to deform when extruded and round off into
spherical granules on spheronisation. The composition of the wet mass is
critical in obtaining a high yield of pellets of good quality.
The concentration of water incorporated into the formulation, during the
granulation of the wet mass for extrusion, greatly affects the quality of the
pellets obtained at the end of the process. Usually, the amount of water
required for successful extrusion is about 20-30 % w/w, more than is
needed for granulations for other applications; as water is needed to serve
as a lubricant to facilitate the smooth entry and passage of the wet mass
through the extruder die [25]. Optimum water content can be determined
by preparing granulations of varying water content and subjectively
assessing which formulation has the water level most suitable for
extrusion. This assessment is based on ease of processing, extrudate
quality, deformation characteristics and properties of the spheres
produced.
Fluffy, insufficiently wetted formulations require high extrusion forces
making processing difficult and generating high amounts of friction and
pressure within the equipment, which can damage the extruder [11].
Extrudates obtained from such masses will also be observed to have poor
surface characteristics, high friability and will likely not deform into good
spheres. However, overly wet masses are problematic in that they stick to
equipment parts and cluster together to form larger spheres resulting in
poor size distribution [11].
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Wet massing
Extrusion
Spheronisation
Drying Screening
Dry blending of excipients
The granulating fluid concentration required for a particular drug
formulation has been found to decrease linearly as a function of the
natural log solubility of the drug in question [39]. Hence, the water
content of the formulation will have greater implications in the formulation
of drugs with high water solubility.
1.8 Process Outline
Conine and Hardley [40] described the steps involved in the manufacture
of spheronised pellets as the following:
Fig. 3: Process Outline for the Production of Spheronised Pellets.
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1.8.1 Dry Mixing
This entails blending the drug and excipients in the dry state to achieve
homogeneous powder dispersion prior to granulation.
This is done to prevent localised overwetting that can result from a non-
uniform distribution of powders of varying size and solubility resulting in
pellets with an uneven size distribution.
1.8.2 Wet Massing
This is the process of mixing the uniform powder blend prepared earlier
with an adequate quantity of granulating fluid to obtain a moistened mass
that is cohesive and plastic enough for extrusion/spheronisation. The wet
mass obtained should also posess sufficient inherent fluidity and self
lubricating properties, permitting flow under a constant pressure as the
mass enters and passes through the die.
Conventional mixers and granulating equipment are normally used, but it
is pertinent to guard against heat build up from such equipment especially
the high shear mixers which generate very high temperatures leading to a
greater than acceptable degree of evaporation of granulating fluid, or
increase in solubility of dispersed solids and an associated reduction in
plasticity [41].
1.8.3 Extrusion
This refers to the formation of rod shaped granules of uniform diameter by
forcing the mass through an extrusion screen that consists of dies of
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uniform diameter. Extruders come in various designs and are grouped into
three classes based on their feed mechanism: screwfeed extruders,
gravity-feed extruders and piston-feed extruders.
The extrudates produced should have sufficient mechanical strength,
smooth surface properties; possess enough plasticity to deform under
their own weight on extrusion and form spheres that do not adhere to
each other in the spheroniser.
1.8.4 Spheronisation
Here, extrudates are rounded off into spherical granules in the spheroniser
which consists of a cylindrical bowl with a fast-rotating friction plate at the
base. Spheronisation is brought about by frictional forces generated
between the particles and/or the particle and equipment [11]. The bottom
plate is grooved to increase these forces and two geometric patterns are
available: a cross-hatched pattern with grooves running at right angles to
each other and a radial pattern with grooves running from the centre of
the disc [23].
Spheronisation occurs in stages and can take between 2-15 minutes
depending on the properties of the formulation being processed. The
acceptable spheronisation speed required to produce a spherical particle
varies widely. Recently more emphasis has been placed on evaluating not
just the absolute rotational speed of the friction plate, but the peripheral
velocity of the plate which can be derived using a combination of the
speed and diameter of the friction plate to assess the performance of a
19
given formulation [42].
1.8.5 Drying
This is essential to achieve acceptable moisture content of the product.
Drying can be done using the tray drier or fluidised bed drier.
1.8.6 Screening
A nest of sieves is used to seperate pellets into different size distributions.
1.9 Pelletisation process variables
Processing factors that influence the properties of pellets obtained from
the process of extrusion and spheronisation are stated in the table below:
Table 1: Processing variables
Dry Mixing
Equipment type; mixing time
Wet massing
Equipment type; type and concentration of granulating fluid.
Extrusion
Extruder type; diameter and length of extruder die; extrusion speed; feed
rate.
Spheronization
Equipment type; product residence time; spheronisation speed; product
charge.
20
1.10 Coating Technologies
Pharmaceutical solid dosage forms are either coated in a bid to alter their
taste, improve their appearance or offer protection from light or humidity,
termed ‘plain coatings’ by the USP [43], or to confer modified release
characteristics on the dosage form (controlled release coatings).
Controlled release coatings include enteric coating and other forms of рH 
sensitive coatings, non-enteric polymeric coatings and enzyme-degradable
coatings. The focus of this research will be on рH-dependent coatings.
1.10.1 Enteric coatings
These can be used to protect susceptible APIs from degradation in the
acidic contents of the stomach; prevent local irritation of the GIT mucosal
lining by certain drugs; provide a delayed release component for repeat
action tablets [43] and/or facilitate drug delivery to distal regions of the
gut.
рH-sensitive polymers most commonly used to achieve targeted drug
release for oral dosage forms are the methacrylic acid polymers
(Eudragits®).
1.10.2 Eudragit® polymers
These are synthetic cationic and anionic copolymers of
dimethylaminoethylmethacrylates, methacrylic acid and methacrylic acid
esters mixed in varying proportions.
Eudragits used in the formulation of enteric coatings and targeted drug
release products includes: Eudragit® L, S, FS and E which have acidic or
21
alkaline functional groups and selectively effect drug release by salt
formation at target рH values at which they are soluble in digestive fluids.
Eudragit® RL, RS and Eudragit® NE polymers with alkaline and neutral
groups respectively are impermeable in digestive fluids. They are often
used for sustained drug release because they offer timed release of the
API by рH -independent swelling of the dosage form [44].
These polymers are available from the manufacturer as aqueous
dispersions, powders or organic solutions to be applied as coatings to oral
dosage forms.
For colonic drug targeting, Eudragit® S and Eudragit® FS30D that dissolve
at рH 7.0 can be used. Eudragit® FS30D has good film forming properties,
requires no plasticizer and is favoured for coating multiparticulates due to
its mechanical flexibility (44).
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2. MATERIALS AND METHODOLOGY
2.1 Materials
Cystamine-phenylalanine conjugate was synthesized within RGU
laboratories; microcrystalline cellulose (Avicel® PH 101) was obtained
from FMC Ltd. (Cork, Ireland). Dibasic calcium phosphate (Emcompress®)
was from Penwest GMBH (Germany) and lactose was from Honeywell and
Stein (London, England).
Theophylline, gellan gum (GelzanTm), triethylcitrate, rice and corn starch,
xanthan, karaya, ghatti, locust bean and guar gum were purchased from
Sigma-Aldrich, UK. Wheat starch was from Fisons Ltd. (Loughborough,
England), potato starch was obtained from Merck GaA
(Dermastadt,Germany), maize starch and glycerol monostearate were
from BDH Chemicals limited (Poole, England).
Methylcellulose (MC) (Methocel®) and simethicone emulsion were from
The Dow Chemical company (Michigan, U.S.A),
hydroxypropylmethylcellulose (HPMC K100M) was from Colorcon Ltd.
(Kent, England), hydroxyethylcellulose (HEC) (Natrosol®) and
hydroxypropylcellulose (HPC) (Klucel®) were from Aqualon (Detroit,
U.S.A). Sodium carboxymethylcellulose (SCMC), croscarmellose sodium
(CCS) and Tween® 80 were from Fisher scientific ltd. (Loughborough,
England).
Food grade gellan gum (Kelcogel®-CGLA and Kelcogel®-CGHA) and
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Eudragit® FS30D were obtained as gifts from Cp Kelco (Atlanta, USA) and
Evoniks Industries (Cheshire, UK services) respectively.
2.2 Methods
2.2.1 Preparation of placebo pellets
Required amounts of extrusion aid and filler were weighed out using
formulation ratios given in Table 2 and dry-blended in a Kenwood
planetary mixer (model: KMC510L, Kenwood Company, USA) at speed 3
for 10 minutes.
Pre-optimisation of the quantity of extrusion aid and distilled water
required for optimum wet mass consistency was done by visual
assessment of the extrusion properties of the wet mass formulation based
on ease of processing, extrudate surface texture, deformation
characteristics and properties of the spheronisation product.
Sufficient amount of distilled water was then gradually incorporated into
the blend and mixing continued at speed 4 for a length of time needed to
yield a homogeneous mass.
The composition of formulations used for subjective comparative
evaluation of wet mass properties is highlighted in the table below:
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Table 2: Formulations of wet masses used in comparative evaluation
studies
Extrusion
aid (g)
Filler (g) Distilled
water (g)
Solids mass
fraction
(wt %)Emcompress® lactose
MCC 50 50 - 66 60.2
HPMC 30 50 - 60 57.1
HPC 20 60 - 30 72.7
MC 30 30 - 40 60.0
SCMC 25 50 - 55 57.7
HEC 25 25 - 40 55.6
CCS 40 40 - 80 50.0
Rice starch 30 40 - 35 66.7
Maize starch 40 50 - 37 70.9
40 - 40 60 57.1
Wheat starch 40 50 - 33 73.1
40 30 36 66.0
Corn starch 30 40 - 30 70.0
30 - 40 30 70.0
Potato starch 30 40 - 25 73.7
30 - 40 25 73.7
Xanthan gum 10 100 - 20 84.6
Karaya gum 8 80 - 30 74.6
Guar gum 7 70 - 45 63.1
Ghatti gum 4 80 - 20 80.8
Locust bean
gum
8 80 - 45 66.1
Gellan gum
(GelzanTm)
3 - 60 20 75.9
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The wet mass was then fed into a laboratory bench-top basket extruder
featuring a 1mm extrusion screen (Caleva Process Solutions Ltd., Dorset,
UK) and the resultant extrudate loaded into a bench-top 120 spheroniser
(Caleva Process Solutions Ltd., Dorset, UK) with a 1mm cross-hatched
friction plate fitted at the base of the spheronisation bowl. Spheronisation
speed was determined and recorded by the use of a tacometer.
Viable pellets produced were dried in a fluidised bed drier (Copley Retsch
TG100, Nottingham, England) at 60oC for 30 minutes and shaken through
a nest of sieves (Copley Retsch As200 Sieve Shaker, Rheinische,
Germany) (mesh size range from 90µm-1mm) for 10 minutes to separate
the pellets into different size distributions. Pellets were then bench-coated
and those from the 710-1000µm size range kept for further
characterisation.
2.2.2 Optimisation of the formulation of gellan pellets.
Results from the above experiment showed that gellan gum had the most
potential for use as an extrusion aid, necessitating the need for optimising
gellan formulations. GelzanTm was used for prior studies, but this product
was taken off the manufacturer’s brochure and replaced with Food grade
Gellan gum (Kelcogel®-CGLA and Kelcogel®-CGHA).
Blends of Kelcogel®-CGLA (CGLA) and Kelcogel®-CGHA (CGHA) in varying
ratios were incorporated into lactose based wet masses as shown in Table
2, to determine if there was a significant potentiation in the desirable
rheological properties of the gum.
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Batches of spheronised pellets were prepared by mixing a dry pre-blend of
low: high acyl gellan gum made using the ratios in Table 3 below with
lactose at a ratio of 1:20 and subsequently mixing in a sufficient amount
of distilled water to give a homogeneous mass.
Table 3: Composition of gellan formulations used for optimisation studies
Blending ratios
(% w/w)
A
(0:100)
B
(25:75)
C
(50:50)
D
(60:40)
E
(65:35)
Formulations (i) (ii) (iii) (iv) (v) (vi) (vii) (viii) (ix)
CGLA (g) 3 - 1 3 2 1.8 1.2 1.95 1.05
CGHA (g) - 3 3 1 2 1.2 1.8 1.05 1.95
LACTOSE (g) 60 60 80 80 80 60 60 60 60
DISTILLED
WATER (ml)
30 18 26 23 18 22 20 20 19
Each wet mass formulation was then processed into pellets as described
earlier and the resultant pellets characterised.
2.2.3 Preparation of drug-loaded pellets
Two batches each of theophylline and cystamine pellets were prepared
varying the extrusion aid used in the formulation
MCC-based theophylline pellets were prepared by wet massing a pre-
blend of 60g dry MCC:Emcompress (1:1) with a solution of 6g of
theophylline in 35mls of distilled water in the planetary mixer. This
formulation was repeated with cystamine pellets, changing the granulating
solution to 6g cystamine phenylalanine conjugate in 40mls of distilled
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water and 0.01ml ethanol added as a cosolvent to hasten dissolution of
the API.
Gellan-based theophylline pellets were prepared by wet massing a dry mix
of 3g CGLA: CGHA blend (65:35 % w/w) and 60g lactose with a solution
of 6.3g theophylline in 37mls distilled water in the planetary mixer.
Cystamine in Gellan formulations were also prepared by dry mixing 6g of
CGLA: CGHA (65:35 % w/w) blend with 60g of lactose in the planetary
mixer, and gradually incorporating a solution of 6.6g of cystamine in
22mls of distilled water and 0.01mls of ethanol until a homogeneous wet
mass was obtained.
The wet masses were subsequently extruded and spheronised into pellets
as described earlier.
2.2.4 Coating of pellets
To facilitate colonic targeting, cystamine and theophylline pellets (10g)
from the 710-1000µm size range were coated in the aeromatic fluidised
bed coater (Gea Process, Switzerland) using an aqueous spray suspension
of Eudragit® FS30D (available as 30% w/v aqueous dispersion), a pH-
sensitive polymer that consists of acidic functional groups which
selectively effect drug release by salt formation at alkaline pH values at
which they are soluble in digestive fluids.
The spray suspension was prepared by homogenising (Silverson
machines, Inc.) the required amounts of triethylcitrate (plasticiser),
polysorbate 80 (emulsifier), glycerolmonostearate (glidant) and drops of
simethicone emulsion (antifoam) in a portion of the heated diluent for 10
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minutes, stirring in the rest of the diluent and pouring this suspension into
the Eudragit dispersion with magnetic stirring.
The spray suspension was then passed through a 0.5mm sieve to remove
films of the Eudragit polymer that may have been formed while mixing
and left to stir continuously on a magnetic stirrer plate. The spray
suspension formulation is stated below and was adapted from the
manufacturer’s current applications brochure [45].
Table 4: Composition of spray suspension for coating pellets
For a 100ml spray suspension:
Ingredient Quantity* Weight (g) Dry
Substance
Eudragit®
FS30D
- 59.77 17.93
Polysorbate
80(33%
aqueous
solution)
1.6 0.88 2.90
Triethyl
citrate
5.0 0.90 0.90
Glycerylmono
Stearate
4.0 0.72 0.72
Distilled
water
- 37.73
Total 100.00 19.84
*expressed as % w/w of dry polymer substance
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The pellets were then filled in 10g batches into the coating chamber of the
fluidised-bed coater (Aeromatic Strea 1 Fluidised Bed Film Coater,
Bubendorf, Switzerland) fitted with a bottom spray, 0.8mm bore injection
nozzle.
Coating process parameters are given below:
Atomising air pressure: 1.8 bar
Inlet air temperature: 40°C
Inlet air volume (fan speed): 10-12 revolutions per minute
Height of wurster column: 8cm
Product bed temperature: 25-30°C
Drying process parameters are given below:
Drying temperature: 50°C
Drying time: 60 minutes
Spray rate: 10ml/minute
The pellets were pre-warmed for 10 minutes and then the spray
suspension was fed into the coater using a peristaltic pump (HR Flow
Inducer, Cornwall, England). The pump was switched off intermittently
during the spraying process to prevent overwetting and agglomeration of
the pellets. Different batches of pellets were coated with successively
increasing amounts of spray suspension (15-30ml) yielding pellets with
varied coating thickness.
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The effectiveness of the applied coating in terms of retardation of drug
release was determined by carrying out dissolution tests in 0.1M HCl.
25ml of spray suspension (equivalent to 4.5g of dry Eudragit® FS30D per
10g of pellets) was found to give an optimum pellet coating thickness that
retarded drug release to less than 5% in 0.1M HCl, while ensuring drug
release in pH 7.4 phosphate buffer was not inhibited.
After delivering the spray suspension, the pump was switched off and the
pellets left to dry at 50°C for one hour in the same equipment.
2.3 Characterisation and evaluation of pellets
2.3.1 Pellet Size Distribution Analysis
The dried pellets were shaken through a ‘nest of sieves’ with progressively
smaller mesh sizes from top to bottom ( 1mm, 710µm, 500µm, 355µm,
250µm, 180µm, 125µm and 90µm) for 10 minutes at an amplitude of
1.5mm/’g’. Each sieve fraction of pellets was weighed and the value
expressed as a percentage of the total weight of pellets before sieving.
The percentage pellet size distribution of the formulation was analysed by
plotting the percentage weight of pellets retained on each sieve against
the corresponding mesh size.
A good formulation yields pellets with a narrow size distribution. The mesh
sizes given above had a modal size distribution of 710-1000µm and pellets
from this sieve fraction were retained for further characterisation and
coating.
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2.3.2 Sphericity evaluation
Microscopic examinations of samples of 20 pellets obtained randomly from
the 710µm size distribution of each batch of viable pellets was carried out
using a standard laboratory microscope (Leica DFC 420), set to a
magnification of x 5.
Pellet shape was then assessed subjectively by allocating a figure to each
pellet in an order that correlates with its relative degree of sphericity, on a
visual scale of 0-5. Therefore, the most spherical pellets were awarded a
‘5’, while irregular non-spherical ones were furthest down the scale as
shown in the diagram below.
5 4 3 2 1 0
perfect spheroid irregular ellipsoid dumbbell rounded
sphere spheroid cylinder
Fig. 4: Diagrammatic representation of classification of pellets based on
their visual appearance
The average sphericity of each sample was calculated by dividing the
summation of the various figures allocated to each pellet by the number of
pellets in the distribution. The average sphericity value obtained was
expressed as a percentage of the value corresponding to a perfectly
spherical pellet i.e. ‘5’ to obtain the percentage sphericity of a formulation.
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2.3.3 Bulk density and Flowability Determination
This was determined by carrying out tapped density and bulk density
measurements. Pellets (10g) were weighed and placed in a measuring
cylinder to determine the initial volume and density referred to as the
‘poured or fluff density’, Do. The cylinder was then tapped mechanically
1280 times using a volumeter (Copley Tap SVM 22 Volumeter,
Nottingham, England) and the volume of pellets after tapping noted and
used to determine the ‘tapped or consolidated bulk density’ Df.
Hausner’s ratio, Df/Do was calculated for each batch of pellets and used as
a gauge for predicting pellet flow properties [46].
The percentage compressibility of the pellets, also known as Carr’s
compressibility index (%) was also calculated using the equation below:
Df - Do/ Df x 100. (Equation 1)
Where, Df = Tapped density
Do = Bulk density
Values ranging from 5-16% indicate pellets with adequate flow properties,
according to Carr [47]. Free-flowing pellets are critical in ensuring uniform
and reproducible pellet filling and packaging.
2.3.4 Pellet Friability determination
Pellets (5g) were weighed and rotated for 30 minutes in a friabilator
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(Erweka GMBH, Germany). The pellets were then sieved to get rid of
broken pieces and re-weighed.
The percentage weight loss of the pellets after agitation in the friabilator
was calculated and recorded. Friability values less than 2% are
recommended for pellets to be able to withstand coating processes [44].
2.3.5 Dissolution testing
A series of in vitro dissolution tests using the USP 2 rotating basket
method were carried out on different formulations of coated and uncoated
pellets containing both model and test drug. An on-line dissolution
apparatus (Sotax dissolution apparatus, Basel, Switzerland) connected to
a UV spectrophotometer (Lambda 40 UV/VIS, PerkinElmer Instruments
USA) was used to measure the concentration of drug released from the
pellets at set times. The pellets were placed in separate rotating baskets
positioned within dissolution flasks containing 900ml of the required
dissolution medium at 37 +/- 0.5 oC, and rotating at a speed of 100rpm.
Samples of uncoated and coated cystamine and theophylline pellets
(pellet weights equivalent to 300mg cystamine and 30mg theophylline )
were analysed at 256nm and 275nm respectively in 0.1N HCl for 1 hour,
and subsequently transferred to phosphate buffer pH 7.4 where
applicable, to assess their release profile in both media. Drug release
profiles were obtained by measuring ‘absorbance’ values every 5 minutes
and the percentage of drug dissolved in the dissolution medium at a
specific time computed automatically using precalculated A [1%, 1cm]
values obtained from the calibration curve.
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For each formulation, triplicate values were obtained and the rate of drug
release in each medium evaluated by plotting the mean percentage drug
dissolution against time. Colon-targeted pellets coated with Eudragit
FS30D should be gastro resistant, retarding the release of the drug in acid
medium (0.1N HCL), while effecting drug release in a buffer at similar pH
conditions to the colon (pH 7.4).
2.3.6 Scanning electron microscopy (SEM) imaging
Scanning electron microscopy (Leo S430 scanning electron microscope)
imaging was undertaken on a selection of cystamine pellet samples
containing MCC and gellan gum respectively.
Dried samples were mounted using double-sided tape on aluminium stubs
and gold sputtered (SC7640 Plasma Magnetron Sputter Coater) prior to
imaging.
A magnification of X 55 and X 200 was sufficient to reveal multiparticulate
morphology.
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3. RESULTS
3.1 Extrusion-spheronisation attributes of polymer formulations
Table 5: *Comparative evaluation of extrusion characteristics of polymers
Wet mass Extrudates pellets
cohesive fluid sticky plastic friable deform round discrete hard
MCC +++ +++ - +++ - +++ +++ +++ +++
HPMC +++ - +++ - - - - -
HPC +++ - +++ - - - - - -
MC +++ - +++ - - - - - -
SCMC +++ +++ + + - + - - -
HEC - - - - +++ - - - -
CCS - - - - +++ - - - -
Rice ++ ++ - +++ + +++ ++ +++ -
Maize ++ ++ - +++ + +++ ++ +++ -
Wheat ++ ++ - +++ + +++ ++ +++ -
Corn ++ ++ - ++ + +++ + +++ -
Potato ++ ++ - - - - - - -
Xanthan +++ +++ - +++ +++ ++ - +++
Karaya +++ +++ - +++ - +++ ++ - +++
Ghatti +++ +++ - +++ - +++ ++ - +++
Guar +++ ++ + - - - - - -
Locust bean +++ ++ + - - - - - -
GelzanTm +++ +++ - +++ --- +++ ++ +++ ++
*Key: +++ - excellent; ++ - good; + - average; - - none
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3.2 Optical micrograph of spheronisation products
Fig. 5: Spherical pellets from an MCC-based wet mass (x 5).
Fig. 6: Rod-like spheronisation product of an HPMC-based wet mass (x 5).
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Fig. 7: Spherical but friable wheat starch pellets; note the edges
of the pellets appear crumbly (x 5).
Fig. 8: Aggregates of karaya gum pellets (x 5).
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3.3 Characterisation of gellan pellets
Optimum gellan combinations in terms of sphericity and size distribution
were identified as Formulation D(vi) containing 60% CGLA/ 40% CGHA
and Formulation E(viii) containing 65% CGLA/ 35% CGHA as extrusion
aids.
Results of physical characterisation of these pellets were compared with
data obtained from characterisation of spheronised pellets containing
MCC, CGLA and CGHA separately as sole extrusion aid.
Key : Type and proportion of extrusion aid used
MCC- 100% MCC;
Formulation A (i) – 100% CGLA;
Formulation A (ii) – 100% CGHA;
Formulation D (vi) - 60% CGLA/ 40% CGHA;
Formulation E (viii) – 65% CGLA/ 35% CGHA.
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3.3.1 Pellet size distribution analysis
Fig. 9: Pellet size distribution analysis: the size distribution of CGLA
pellets (A(i)) was improved by combining it with CGHA, with a large
proportion of the pellets obtained being retained within a modal size range
(710-1000µm mesh size).
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3.3.2 Sphericity evaluation
Fig. 10: Pellet sphericity evaluation: Formulations of gellan pellets
composed of a combination of CGLA and CGHA (D(vi) and E(viii))
contained a higher percentage of spherical pellets than was observed with
formulations containing either CGLA or CGHA alone (A(i)or A(ii)).
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3.3.3 Optical micrograph of gellan pellets
Fig. 11: Pellets from Formulation A(i) (100% CGLA) (x 5)
Fig. 12: Pellets from Formulation E(viii) (65% CGLA/ 35% CGHA ) (x 5)
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3.3.4 Pellet Friability and Flowability Determination
Table 6: Pellet friability and flowability indices including poured density
(Do), tapped density (Df), compressibility (comp) and Hausner’s Ratio
(HR).
Formulation Friability Flowability indices
Do Df Comp (%) HR
MCC 0.01 0.88 0.99 11.10 1.13
A(i) 0.63 0.66 0.70 5.71 1.17
A(ii) 0.42 0.67 0.69 2.90 1.03
D(vi) 0.92 0.69 0.73 5.50 1.06
E(viii) 0.98 0.69 0.74 6.80 1.07
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3.4 Drug release profile of pellets
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Fig. 13: Dissolution of MCC-based theophylline pellets where C denotes
coated pellets; UC – uncoated pellets; PB 7.4 – phosphate buffer pH 7.4
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Fig. 14: Dissolution of gellan-based theophylline pellets where C denotes
coated pellets; UC – uncoated pellets; PB 7.4 – phosphate buffer pH 7.4
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Figure 13 and 14 shows the dissolution profile of coated and uncoated
theophylline pellets containing MCC (Fig 13) and gellan (Fig 14) in 0.1M
HCl and phosphate buffer.
In 0.1M HCl, all uncoated pellets showed an almost complete release of
the drug (>90%). However, while MCC-based pellets exhibited a steady
but gradual drug release pattern (Fig 13), gellan pellets demonstrated a
more rapid and immediate release of the drug (Fig 14). The ability of the
Eudragit coating to limit drug release in acidic media was evident from the
dissolution curves of coated MCC and gellan based theophylline pellets in
0.1M HCl, which are almost level with the baseline.
The dissolution profiles obtained for theophylline pellets containing MCC
and gellan in phosphate buffer were similar. Drug release was minimal
(< 12%) and incomplete for uncoated and coated pellets.
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Fig. 15: Dissolution of MCC-based cystamine pellets where C denotes
coated pellets; UC – uncoated pellets; PB 7.4 – phosphate buffer pH 7.4
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Fig. 16: Dissolution of gellan-based cystamine pellets where C denotes
coated pellets; UC – uncoated pellets; PB 7.4 – phosphate buffer pH 7.4
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Figure 15 and 16 shows the dissolution profile of coated and uncoated
cystamine pellets containing MCC (Fig 15) and gellan (Fig 16) in 0.1M HCl
and phosphate buffer.
In acidic media, uncoated cystamine pellets containing MCC showed a
steady but gradual increase in dissolution rate (Fig 15), while pellets
containing gellan exhibited a rapid and immediate drug release in 0.1M
HCl (Fig 16). However, for both pellet formulations drug release was
incomplete in 0.1M HCl, as only 40-50% of the drug was released from
the pellets within one hour. Drug release from coated pellets was
negligible in 0.1M HCl, with the Eudragit coating reducing the amount of
drug dissolved to less than 5% in one hour.
In phosphate buffer, both MCC and gellan based uncoated cystamine
pellets exhibited almost instantaneous and total release of the drug.
Coated pellets in phosphate buffer showed a steady and gradual increase
in the amount of drug dissolved, till almost the entire drug (>80%) was
released at the end of one hour.
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3.5 Scanning electron microscope images of cystamine pellets
Fig. 17: Uncoated MCC-based cystamine pellets (x 55).
Fig. 18: An uncoated MCC-based cystamine pellet (x 200).
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Fig. 19: Coated MCC-based cystamine pellets (x 100), note the surface
smoothening effect of the coating on the pellets.
Fig. 20: A coated MCC-based cystamine pellet (x 200).
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Fig. 21: Uncoated gellan-based cystamine pellets (Formulation Eviii) (x
55), note their high degree of sphericity.
Fig. 22: An uncoated gellan-based cystamine pellet (x 200).
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Fig. 23: Coated gellan-based cystamine pellets (x 55).
Fig. 24: A coated gellan-based cystamine pellet (x 200).
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4. DISCUSSION
4.1 Evaluation of extrusion-spheronisation properties of
polymers
In the formulation and manufacture of spheronised pellets, the polymer
chosen to function as an extrusion aid in the formulation determines to a
great extent the physical properties of pellets produced. Based on the
peculiar rheology of the extrusion aid and its interaction with that of other
components of the formulation, the process of extrusion and
spheronisation could be adequately facilitated to the point where perfect
pellets are produced, or no pellets are obtained at all after spheronisation.
Essentially, a polymer intended for use as an extrusion aid should be able
to impart the properties of plasticity, fluidity and cohesiveness to a wet
mass to facilitate and maintain sequential shape changes that are critical
in its extrusion and spheronisation into pellets. So far, microcrystalline
cellulose has been widely used as a standard extrusion aid due to its
ability to confer a high degree of plasticity to wet mass formulations. In
combination with equal proportions of Emcompress®, MCC-based wet
masses at optimum water concentration (40% w/w) where found to yield
hard spherical pellets within minimal spheronisation times of 5-8 minutes.
Obtaining pellets of similar quality from optimal formulations of other
cellulosic polymers like HPMC, MC, HPC and SCMC was not possible, as
was highlighted in Table 5.
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This was essentially due to the production of smooth coils of very elastic
extrudate that are unable to deform into pellets after prolonged
spheronisation. Other cellulose derivatives like HEC and CCS impart little
or no cohesive forces and fluidity to the wet mass, making processing
difficult and leading to the formation of severely shark-skinned, friable
extrudates that disintegrate in the spheroniser.
Starches (maize, wheat, rice and waxy corn starch) were observed to be
easily spheronised into round pellets with smooth surfaces but very low
mechanical strength, fragmenting when handled (pellet friability values:
wheat -7.92% ; rice – 8.4%; maize -10.57%). Natural gums such as
xanthan, karaya and ghatti gum yielded smooth extrudates, plastic
enough to deform into fairly round pellets after spheronising for 10-12
minutes. However, the sticky nature of the gums caused the pellets
obtained to clump together into aggregates during spheronisation, making
it impossible to collect pellets as discrete units even after drying in the
fluidised bed drier. Potato starch, locust bean and guar gum wet masses
were found to produce elastic extrudate that barely deforms on
spheronisation.
Gellan blends incorporated into lactose-based wet masses at ratios of
1:20 (gellan:lactose) produced round, discrete pellets of acceptable
mechanical strength within spheronisation times of 8-10 minutes. Surface
texture of gellan pellets was observed to be smoother with lactose being
used as the filler rather than Emcompress®. On evaluation of the
aforementioned observations, gellan gum was found to show the most
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potential for being a suitable extrusion aid, and subsequent work was
focused on optimising the properties and yield of pellets obtained from
gellan based wet mass formulations.
4.2 Evaluation of the properties of optimised gellan formulations
Optimisation of the extrusion properties of gellan formulation was geared
towards obtaining a wet mass that would support the production of a high
proportion of spherical pellets within a narrow size range.
Batches of pellets prepared using CGLA (Formulation A(i)) as the sole
extrusion aid were seen to have a wide size distribution, with a high
percentage of dumbbells retained on the 1mm sieve and low percentage
of very spherical pellets on the 710 µm and 500 µm sieves. This is
presumably because CGLA forms brittle gels when wetted due to the low
levels of acylation of the gum [36]. Therefore, spheronisation times are
long (18-20 minutes) and results in breakage of the extrudates into longer
rods partially deformed into dumbbells and short rods that are
spheronised into pellets.
On the other hand, high acyl gellan gum CGHA characteristically forms
soft elastic gels when wetted [36].Hence, pellets containing only CGLA
show a reduced tendency to deformation as is often encountered with
elastic materials and hence have poor sphericity.
Optimisation studies involved identifying the desirable properties of either
grade and combining both grades of the gum in different ratios to
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potentiate these extrusion properties and provide a favourable gel texture
for successful extrusion and spheronisation. All formulations containing
blends of CGLA and CGHA showed improved pellet size distribution.
Formulation D(vi) and E(viii): 60% CGLA/ 40% CGHA; 65% CGLA/35%
CGHA respectively yielded high proportion of spherical pellets on the 710 -
1000µm mesh as shown in Figure 9 and were retained for further
characterisation.
These formulations were also found to possess sufficiently low friability to
withstand normal handling stresses and comply with the Eudragit
manufacturer’s friability limits for pellets intended for coating purposes
(< 2% friability) [43]. The results from the flowability determinations of
pellet Formulations D(vi) and E(viii) as highlighted by the Hausner’s Ratio
and Carr’s Compressibilty Index were desirable. For Hausner’s Ratio,
values below 1.25 indicate acceptable flowability [45] (Formulation D(vi) -
1.06; Formulation E(viii) – 1.07), while Carr’s indices between 5-15%
indicate excellent flow properties [45].
However, it is important to note that the following results are obtained
from the assessment of placebo pellets and the incorporation of an API
significantly affects the physical properties of the resultant drug-loaded
pellets, especially in cases where a high dose or concentration of the API
is required. Thus extrusion aids need to be sufficiently robust to withstand
to an appreciable extent, fluctuations in wet mass properties caused by
changes in formulation excipients. The results show that the physical
properties of pellets from Gellan formulation D(vi) were not as good as
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was observed with MCC. However, gellan Formulation E(viii), closely
replicated the properties of MCC formulations and can be used as a
suitable extrusion aid for the production of spheronised pellets.
The suitability of gellan gum as an extrusion aid may likely be due to the
presence of several free hydroxyl groups within its structure, enabling the
formation of intermolecular hydrogen bonds with water molecules. MCC
has been observed to have about 3% of absorbed water bound to
hydroxyl groups within its amorphous parts [26]. This sort of linkages with
water molecules enables these polymers to entrap water within their
structure thereby improving the rheology of the wet mass and facilitating
the pelletisation process.
Reducing production costs by replacing high quantities of the costly
microcrystalline cellulose with low quantities of gellan gum as an extrusion
aid will still produce spheronised pellets of acceptable quality and efficacy.
Therefore, future development work in the field of extrusion and
spheronisation should focus on the use of gellan gum as a much needed
alternative to MCC.
4.3 Evaluation of the effectiveness of coated pellets in
facilitating colon-specific drug delivery
For the purpose of this work, the application of a pH-dependent polymer
coating on the pellets was chosen as the method of achieving colon
targeted drug delivery due to its inherent simplicity, ease of application
and high degree of effectiveness. Eudragit® FS30D was selected as the
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pH-dependent polymer of choice, based on the manufacturers literature
and specifications [43].The application of an optimum coating of Eudragit®
FS30D on drug loaded pellets should ensure the release of less than 5% of
the drug in 0.1M HCl within one hour while also ensuring that greater than
80% of the drug is released in phosphate buffer pH 7.4, similar to pH
conditions found in the colon [43].
The results of dissolution tests on both coated and uncoated pellets
indicated the effectiveness of sufficiently thick and uniform coatings of
Eudragit® FS30D in retarding drug release in 0.1M HCl. However,
theophylline pellets were observed to be unable to release greater than
12% of the total concentration of the drug incorporated in phosphate
buffer pH 7.4. Although, 100% of the drug was released from uncoated
theophylline pellets in 0.1M HCl.
The reason for this anomalous dissolution behaviour of theophylline pellets
in phosphate buffer is unclear. But, a possible explanation could be solid-
state transformation of anhydrous theophylline on absorption of water into
its lattices to form the less soluble theophylline monohydrate [48]. This
sort of phase transformation has been well documented for theophylline,
and can be induced by the presence of a supersaturated solution and
aggravated by the presence of certain excipients in the formulation [48,
49, 50, 51]. Transformation of anhydrous theophylline to theophylline
monohydrate reduces the dissolution rate of the drug considerably, as the
dissolution rate changes to the lower dissolution rates of the monohydrate
[49].
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Solid-state transformation may occur during processing (especially with
wet granulation processes that involve the use of high quantities of
water), during storage under humid conditions or during dissolution [50,
51, 52].
The formation of theophylline monohydrate has been found to be
aggravated by the presence of MCC due to its high water retaining
capacity and the presence of water-soluble fillers like lactose that increase
the volume of the liquid phase [51]. Also, solution-mediated
transformation which causes slowing down of dissolution rates during a
dissolution process due to recrystallization of drugs into the less soluble
crystalline forms have been found to be dissolution-media dependent and
can lead to abnormal dissolution behaviour [52,53]. In-process monitoring
of pseudopolymorphic transitions of drugs can be done using near-infrared
spectroscopy and Raman spectroscopy [54].
On the other hand, uncoated cystamine pellets showed slow but
consistent release of the drug in 0.1M HCl and rapid release of the drug in
phosphate buffer pH 7.4.Subsequent coating of cystamine pellets (10g)
with 4.5g of Eudragit® FS30D retarded drug release to less than 5% in
0.1M HCl for one hour, while excellent and consistent release of greater
than 90% of the drug was observed in phosphate buffer pH 7.4 in an
hour. However, gellan gum and microcrystalline cellulose based drug
loaded pellets where observed to have similar rates of drug dissolution
from the pellet matrix.
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Future research focused on optimising the use of effective pH-sensitive
polymer coatings like Eudragit® FS30D to produce colon-targeted
multiparticulate pellets would be a way forward in combating the
unpleasant GIT side effects caused by oral administration of cysteamine.
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5. CONCLUSION
The above research findings have highlighted the possibility of replacing
high concentrations of microcrystalline cellulose used in the production of
spheronised pellets with far lesser quantities of cheaper alternatives like
gellan gum, without necessarily compromising the quality and
acceptability of pellets produced.
These oral multiparticulate dosage forms have also been shown to be
potentially suitable as colon-targeted delivery systems, when coated with
pH-sensitive polymers for delivery of cystamine.
Successful colonic delivery of cysteamine will greatly reduce the
discomforting and unpleasant gastrointestinal side effects of the drug,
thereby facilitating patient compliance and safety.
These beneficial effects will translate eventually into less costly
pharmaceutical products, affordable healthcare and an overall
enhancement in the quality of life of patients suffering from cystinosis.
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